Analysts expect Cogent Biosciences to report a Q3 2026 net loss of $0.56 per share on zero revenue, with the current stock price of approximately $31.06 trading well below the average analyst target of $55.82.
The primary focus for investors remains the clinical and regulatory progress of bezuclastinib, the company’s lead candidate for systemic mastocytosis and gastrointestinal stromal tumors (GIST).
Following the FDA's recent acceptance of the New Drug Application for bezuclastinib in advanced systemic mastocytosis, market participants are looking for updates on the Phase 3 PEAK and Phase 2 SUMMIT trials. Investors are also monitoring the company's cash runway as it approaches critical regulatory milestones and potential commercialization phases in 2027.